These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24529221)

  • 1. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report.
    Luyckx E; Eyskens F; Simons A; Beckx K; Van West D; Dhar M
    Clin Neurol Neurosurg; 2014 Mar; 118():9-11. PubMed ID: 24529221
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cerebrotendinous xanthomatosis].
    Burghaus L; Liu W; Haupt WF
    Dtsch Med Wochenschr; 2007 Jul; 132(27):1463-6. PubMed ID: 17583829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrotendinous xanthomatosis: a treatable cause of metabolic ataxia.
    Mukherjee AA; Chawla BP; Rathi SS; Puthran RS
    J Assoc Physicians India; 2007 Sep; 55():655-7. PubMed ID: 18051740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.
    Berginer VM; Gross B; Morad K; Kfir N; Morkos S; Aaref S; Falik-Zaccai TC
    Pediatrics; 2009 Jan; 123(1):143-7. PubMed ID: 19117873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrotendinous xanthomatosis in three siblings from a Chinese family.
    Ko KF; Lee KW
    Singapore Med J; 2001 Jan; 42(1):30-2. PubMed ID: 11361235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Late-onset and Relatively Rapidly Progressive Case of Pure Spinal Form Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.
    Takasone K; Morizumi T; Nakamura K; Mochizuki Y; Yoshinaga T; Koyama S; Sekijima Y
    Intern Med; 2020 Oct; 59(20):2587-2591. PubMed ID: 32581172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
    Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
    Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of 7α-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report.
    Matysik S; Orsó E; Black A; Ahrens N; Schmitz G
    Chem Phys Lipids; 2011 Sep; 164(6):530-4. PubMed ID: 21679699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
    Dotti MT; Lütjohann D; von Bergmann K; Federico A
    Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical reasoning: a case of treatable spastic paraparesis.
    McKinnon JH; Bosch EP
    Neurology; 2012 Aug; 79(6):e50-3. PubMed ID: 22869688
    [No Abstract]   [Full Text] [Related]  

  • 12. Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis.
    Caroppo P; D'Agata F; Mignarri A; Stromillo ML; Dotti MT; Mongini T
    Neurol Sci; 2013 Sep; 34(9):1693-6. PubMed ID: 23212406
    [No Abstract]   [Full Text] [Related]  

  • 13. Chenodeoxycholic treatment of cerebrotendinous xanthomatosis.
    Samenuk P; Koffman BM
    Neurology; 2001 Mar; 56(5):695-6. PubMed ID: 11245734
    [No Abstract]   [Full Text] [Related]  

  • 14. [The right medicine for cerebrotendinous xanthomatosis].
    Verrips A; Wevers RA; van Spronsen FJ; Sikkens H
    Ned Tijdschr Geneeskd; 2009 Apr; 153(15):726-7. PubMed ID: 19452779
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cerebrotendinous xanthomatosis--a treatable metabolic disorder].
    Sperhake JP; Matschke J
    Nervenarzt; 2004 Jun; 75(6):608. PubMed ID: 15257383
    [No Abstract]   [Full Text] [Related]  

  • 16. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
    Ito S; Kuwabara S; Sakakibara R; Oki T; Arai H; Oda S; Hattori T
    J Neurol Sci; 2003 Dec; 216(1):179-82. PubMed ID: 14607320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins for high-risk patients without heart disease or high cholesterol.
    Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins.
    Sukhija R; Aronow WS; Sandhu R; Kakar P; Babu S
    Am J Cardiol; 2006 Jan; 97(2):279-80. PubMed ID: 16442379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.